Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma |
Do Seon Song, Si Hyun Bae |
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea |
|
Abstract |
Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to
the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory
efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment
modalities are required. Recent studies reported that treatment modalities other than
sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization,
showed comparable or better response rates and survival rates than sorafenib. In this review,
treatment modalities that could be used as alternatives to sorafenib will be discussed. (J Liver
Cancer 2016;16:1-6) |
Key Words:
Hepatocellular carcinoma; Sorafenib; Hepatic arterial infusion chemotherapy; Radioembolization |
NULL |
|